Meiji Yasuda Life Insurance Co Raises Stake in Merck & Co., Inc. (NYSE:MRK)

by · The Markets Daily

Meiji Yasuda Life Insurance Co boosted its holdings in shares of Merck & Co., Inc. (NYSE:MRK – Free Report) by 31.4% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 111,802 shares of the company’s stock after acquiring an additional 26,725 shares during the period. Meiji Yasuda Life Insurance Co’s holdings in Merck & Co., Inc. were worth $13,841,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the business. Wellington Management Group LLP lifted its position in Merck & Co., Inc. by 3.8% during the 4th quarter. Wellington Management Group LLP now owns 85,595,999 shares of the company’s stock valued at $9,331,676,000 after acquiring an additional 3,153,333 shares during the period. Royal Bank of Canada raised its holdings in Merck & Co., Inc. by 12.8% in the fourth quarter. Royal Bank of Canada now owns 14,972,074 shares of the company’s stock worth $1,632,255,000 after buying an additional 1,696,151 shares during the last quarter. Capital World Investors raised its holdings in Merck & Co., Inc. by 67.6% in the first quarter. Capital World Investors now owns 13,954,017 shares of the company’s stock worth $1,841,233,000 after buying an additional 5,627,923 shares during the last quarter. Fisher Asset Management LLC raised its holdings in Merck & Co., Inc. by 1.6% in the fourth quarter. Fisher Asset Management LLC now owns 13,551,242 shares of the company’s stock worth $1,477,357,000 after buying an additional 212,852 shares during the last quarter. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main raised its holdings in Merck & Co., Inc. by 2.2% in the fourth quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 12,050,924 shares of the company’s stock worth $1,313,741,000 after buying an additional 253,981 shares during the last quarter. 76.07% of the stock is owned by hedge funds and other institutional investors.

Merck & Co., Inc. Stock Performance

Shares of NYSE MRK opened at $118.30 on Wednesday. The firm has a 50 day moving average of $118.47 and a 200 day moving average of $124.44. The company has a current ratio of 1.47, a quick ratio of 1.22 and a debt-to-equity ratio of 0.80. The firm has a market capitalization of $299.63 billion, a price-to-earnings ratio of 131.44, a price-to-earnings-growth ratio of 1.59 and a beta of 0.39. Merck & Co., Inc. has a 12-month low of $99.14 and a 12-month high of $134.63.

Merck & Co., Inc. (NYSE:MRK – Get Free Report) last announced its earnings results on Tuesday, July 30th. The company reported $2.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.16 by $0.12. The company had revenue of $16.10 billion during the quarter, compared to analyst estimates of $15.87 billion. Merck & Co., Inc. had a net margin of 21.99% and a return on equity of 40.69%. The firm’s quarterly revenue was up 7.1% compared to the same quarter last year. During the same period in the previous year, the business posted ($2.06) earnings per share. On average, research analysts anticipate that Merck & Co., Inc. will post 8.01 earnings per share for the current year.

Merck & Co., Inc. Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, October 7th. Investors of record on Monday, September 16th will be given a dividend of $0.77 per share. The ex-dividend date of this dividend is Monday, September 16th. This represents a $3.08 annualized dividend and a yield of 2.60%. Merck & Co., Inc.’s dividend payout ratio (DPR) is 342.22%.

Analyst Upgrades and Downgrades

MRK has been the subject of several recent analyst reports. UBS Group decreased their target price on shares of Merck & Co., Inc. from $148.00 to $142.00 and set a “buy” rating for the company in a report on Wednesday, July 31st. Bank of America decreased their target price on shares of Merck & Co., Inc. from $150.00 to $145.00 and set a “buy” rating for the company in a report on Wednesday, July 31st. Evercore ISI raised shares of Merck & Co., Inc. to a “strong-buy” rating in a report on Tuesday, July 30th. Barclays decreased their target price on shares of Merck & Co., Inc. from $145.00 to $142.00 and set an “overweight” rating for the company in a report on Wednesday, July 31st. Finally, Morgan Stanley lifted their target price on shares of Merck & Co., Inc. from $132.00 to $134.00 and gave the stock an “equal weight” rating in a report on Thursday, July 11th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, nine have issued a buy rating and four have assigned a strong buy rating to the stock. Based on data from MarketBeat, Merck & Co., Inc. currently has a consensus rating of “Buy” and an average target price of $134.58.

Read Our Latest Analysis on Merck & Co., Inc.

About Merck & Co., Inc.

(Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

See Also